You are here

  • Home
  • Archive
  • Volume 15, Issue 5
  • Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes

https://doi.org/10.1136/ebm1099

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests GB is a consultant for NIH/NIDDK, GSK, Merck, Novartis, Boehringer-Ingelheim, Takeda, Abbott, Walgreen's, BMS/Sanofi, Gilead, Forest, CVRx, Fibrogen, Spherix, Johnson & Johnson, Daiichi-Sankyo. GB has also received investigator initiated grants from GSK Forest Labs.